JP2012530755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530755A5 JP2012530755A5 JP2012516692A JP2012516692A JP2012530755A5 JP 2012530755 A5 JP2012530755 A5 JP 2012530755A5 JP 2012516692 A JP2012516692 A JP 2012516692A JP 2012516692 A JP2012516692 A JP 2012516692A JP 2012530755 A5 JP2012530755 A5 JP 2012530755A5
- Authority
- JP
- Japan
- Prior art keywords
- product according
- pharmaceutical product
- inflammation
- antibody
- excessive inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 14
- 229940127557 pharmaceutical product Drugs 0.000 claims 13
- 102000004127 Cytokines Human genes 0.000 claims 9
- 108090000695 Cytokines Proteins 0.000 claims 9
- 206010061218 Inflammation Diseases 0.000 claims 9
- 230000004054 inflammatory process Effects 0.000 claims 9
- 230000028709 inflammatory response Effects 0.000 claims 9
- 230000003472 neutralizing effect Effects 0.000 claims 8
- 210000004072 lung Anatomy 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229940126601 medicinal product Drugs 0.000 claims 5
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000007613 environmental effect Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000012678 infectious agent Substances 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 3
- 108010074328 Interferon-gamma Proteins 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 239000013566 allergen Substances 0.000 claims 3
- 206010022000 influenza Diseases 0.000 claims 3
- 206010051841 Exposure to allergen Diseases 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000004193 respiratory failure Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000005951 type IV hypersensitivity Effects 0.000 claims 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 241000228212 Aspergillus Species 0.000 claims 1
- 241001453380 Burkholderia Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 206010069767 H1N1 influenza Diseases 0.000 claims 1
- 208000002979 Influenza in Birds Diseases 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 206010001053 acute respiratory failure Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000003092 anti-cytokine Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 201000010740 swine influenza Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0910754A GB0910754D0 (en) | 2009-06-22 | 2009-06-22 | Pharmaceutical agent |
| GB0910754.1 | 2009-06-22 | ||
| GB0913956A GB0913956D0 (en) | 2009-08-10 | 2009-08-10 | Pharmaceutical agent |
| GB0913956.9 | 2009-08-10 | ||
| GB0920790A GB0920790D0 (en) | 2009-11-27 | 2009-11-27 | Pharmaceutical agent |
| GB0920790.3 | 2009-11-27 | ||
| PCT/EP2010/058788 WO2010149641A2 (en) | 2009-06-22 | 2010-06-22 | Pharmaceutical agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012530755A JP2012530755A (ja) | 2012-12-06 |
| JP2012530755A5 true JP2012530755A5 (enExample) | 2013-06-27 |
Family
ID=42727542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516692A Withdrawn JP2012530755A (ja) | 2009-06-22 | 2010-06-22 | 医薬品 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120100155A1 (enExample) |
| EP (1) | EP2424893A2 (enExample) |
| JP (1) | JP2012530755A (enExample) |
| KR (1) | KR20120044937A (enExample) |
| CN (1) | CN102459339A (enExample) |
| AU (1) | AU2010264764A1 (enExample) |
| BR (1) | BRPI1013525A2 (enExample) |
| CA (1) | CA2764257A1 (enExample) |
| RU (1) | RU2012101995A (enExample) |
| WO (1) | WO2010149641A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130245469A1 (en) * | 2012-03-19 | 2013-09-19 | Cardiomems, Inc. | Pulmonary Arterial Hemodynamic Monitoring for Chronic Obstructive Pulmonary Disease Assessment and Treatment |
| DE202013011988U1 (de) | 2012-05-15 | 2015-04-01 | Rajesh Shah | Entzündungshemmende Rezeptur |
| WO2014081958A1 (en) | 2012-11-21 | 2014-05-30 | Cardiomems, Inc. | Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment |
| WO2014145712A1 (en) | 2013-03-15 | 2014-09-18 | Cardiomems, Inc. | Methods for the treatment of cardiovascular conditions |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗ｉｌ３１抗体 |
| CN111214495B (zh) * | 2020-03-02 | 2021-12-31 | 广西医科大学第一附属医院 | 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006044263A2 (en) * | 2004-10-12 | 2006-04-27 | Advanced Biotherapy, Inc. | Treatment of herpes |
| RU2332236C1 (ru) * | 2007-02-02 | 2008-08-27 | Олег Ильич Эпштейн | Лекарственное средство для лечения гриппа у птиц |
| US9598488B2 (en) * | 2008-02-01 | 2017-03-21 | Albany Medical College | Blockage of interferon-gamma for prevention of polymicrobial synergy |
-
2010
- 2010-06-22 EP EP10724534A patent/EP2424893A2/en not_active Withdrawn
- 2010-06-22 WO PCT/EP2010/058788 patent/WO2010149641A2/en not_active Ceased
- 2010-06-22 CN CN2010800269107A patent/CN102459339A/zh active Pending
- 2010-06-22 AU AU2010264764A patent/AU2010264764A1/en not_active Abandoned
- 2010-06-22 CA CA2764257A patent/CA2764257A1/en not_active Abandoned
- 2010-06-22 BR BRPI1013525A patent/BRPI1013525A2/pt not_active IP Right Cessation
- 2010-06-22 KR KR1020117030168A patent/KR20120044937A/ko not_active Withdrawn
- 2010-06-22 RU RU2012101995/15A patent/RU2012101995A/ru unknown
- 2010-06-22 JP JP2012516692A patent/JP2012530755A/ja not_active Withdrawn
- 2010-06-22 US US13/379,996 patent/US20120100155A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Reeth | Cytokines in the pathogenesis of influenza | |
| Nabe | Interleukin (IL)-33: new therapeutic target for atopic diseases | |
| Wark et al. | Respiratory viruses and asthma | |
| Barnes | Cytokine modulators as novel therapies for airway disease | |
| Yamanaka et al. | The role of cytokines/chemokines in the pathogenesis of atopic dermatitis | |
| Petricevich et al. | Increments in serum cytokine and nitric oxide levels in mice injected with Bothrops asper and Bothrops jararaca snake venoms | |
| RU2012101995A (ru) | Фармацевтический агент | |
| US11666636B2 (en) | GLP-1R agonists and uses thereof | |
| CN115209904B (zh) | 透明质酸复合物及透明质酸复合物的用途 | |
| Gulati et al. | Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases | |
| Jafarzadeh et al. | Serum levels of interleukin (IL)-27 in patients with ischemic heart disease | |
| Gambardella | Secukinumab in the treatment of plaque psoriasis in patients with malignancy | |
| Imanirad et al. | Current biologics in asthma treatment | |
| Cottin | Idiopathic eosinophilic pneumonias | |
| Karaman et al. | The effectiveness of asthma therapy alternatives and evaluating the effectivity of asthma therapy by interleukin-13 and interferon gamma levels in children | |
| Fiorenzo et al. | Mechanisms of asthma exacerbations | |
| Esposito et al. | Immunomodulation for recurrent respiratory tract infections: new insights and perspectives | |
| JP2023526536A5 (enExample) | ||
| Li | Advances in the study of cytokine storm mechanisms in pneumonia: an example of IL-6 and IL-33 | |
| Liew et al. | Effect of Diarylpentanoid Analogues on Lipopolysaccharide-Induced Interleukin-6 and Interleukin-8 Gene Expression in Airway Inflammation. | |
| Kaczmarczyk et al. | Upper respiratory tract infection in children–immunostimulating treatment | |
| Jafarzadeh et al. | THE IMMUNOMODULATORY POTENTIALS OF INTERLEUKIN-27 IN AIRWAY ALLERGIES AND COVID-19 | |
| Pasha et al. | Innate Lymphoid Cells in Airway | |
| Petkov | MAJOR DEPRESSIVE DISORDER, TYPE 2 DIABETES MELLITUS AND INFLAMMATION | |
| Reichenbach et al. | Obesity-Mediated Alterations in Immune Function, Host Defense, and Lung Disease |